TET2 Cancer Research Results

TET2, tet oncogene family member 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
TET2 (Ten-Eleven Translocation 2) is a gene that encodes an enzyme involved in the process of DNA demethylation, which is crucial for regulating gene expression and maintaining genomic stability.
TET2 is a critical epigenetic regulator whose dysregulation—mainly through mutations—plays a significant role in the development and progression of various cancers, particularly in hematologic malignancies. Its impact on DNA methylation and subsequent gene expression changes makes it a key player in oncogenesis and a potential target for epigenetic therapies. The prognostic implications of TET2 mutations are context-dependent, contributing valuable information regarding disease progression, patient outcomes, and treatment response.

Loss-of-function mutations or reduced activity of TET2 can lead to aberrant DNA methylation patterns, which may result in inappropriate gene silencing (including of tumor suppressor genes) or activation of oncogenes. This disruption in the normal epigenetic landscape contributes to the development and progression of various cancers, particularly hematological malignancies such as myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
RCC, Renal cell Carcinoma: Click to Expand ⟱
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms.
The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42).
Scientific Papers found: Click to Expand⟱
3119- VitC,    Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
- in-vitro, RCC, NA
TET2↑, TumCG↓, tumCV↓,
3121- VitC,  immuno,    Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma
- in-vivo, RCC, A498 - in-vitro, RCC, 786-O
TET2↑, eff↑, eff↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 2,   TET2↑, 2,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TET2, tet oncogene family member 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:24  Cells:%  prod#:%  Target#:303  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page